ImmixBio IMX-110 Demonstrated Improved Survival Over U.S. Food and Drug Administration Approved Drug Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company) in Connective Tissue Cancer Soft Tissue Sarcoma Mice Study
May 20 2022 - 8:47AM
Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”,
“We” or “Us”), a biopharmaceutical company pioneering
Tissue-Specific Therapeutics (TSTx)™ targeting oncology and
immuno-dysregulated diseases, today announced positive interim
study data showing that after one cycle of treatment, ImmixBio’s
lead candidate IMX-110 produced 75% survival vs. 0% survival for
Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson
Company, a U.S. FDA approved drug) in a connective tissue cancer
Soft Tissue Sarcoma (STS) mice study. In this study, IMX-110 was
compared against approved drugs used to treat STS. Trabectedin was
dosed according to Meco et. al., 2003 (trabectedin monotherapy
treatment arm) and IMX-110 was administered at 2.0 mg/kg.
“We are excited to see continued evidence of IMX-110 anti-tumor
activity versus approved therapies,” said Ilya Rachman, MD PhD, CEO
of ImmixBio. “We believe this is a preview of anti-tumor activity
to be demonstrated in our 2 clinical trials to be kicked-off in
2022: IMX-110 monotherapy, and IMX-110 in combination with
anti-PD-1 tislelizumab.”
About Immix Biopharma, Inc.
Immix Biopharma, Inc. (ImmixBio™) (Nasdaq: IMMX) is a
clinical-stage biopharmaceutical company pioneering a novel class
of Tissue-Specific Therapeutics (TSTx)™ targeting oncology and
immuno-dysregulated diseases. Our lead asset IMX-110, currently in
Phase 1b/2a clinical trials, holds orphan drug designation (ODD) by
the FDA for soft tissue sarcoma, and has received Rare Pediatric
Disease Designation (RPDD) for the treatment of rhabdomyosarcoma, a
life-threatening form of cancer in children. RPPD qualifies
ImmixBio to receive fast track review and a priority review voucher
(PRV) at the time of marketing approval of IMX-110. Our proprietary
SMARxT Tissue-Specific™ Platform produces drug candidates that
circulate in the bloodstream, exit through tumor blood vessels and
simultaneously attack all 3 components of the tumor
micro-environment (TME). We believe ImmixBio’s TME
Normalization™ technology severs the lifelines between the
tumor and its metabolic and structural support. Learn more at
www.immixbio.com.
Forward Looking StatementsThis press release
contains “forward-looking statements” Forward-looking statements
reflect our current view about future events. When used in this
press release, the words “anticipate,” “believe,” “estimate,”
“expect,” “future,” “intend,” “plan,” or the negative of these
terms and similar expressions, as they relate to us or our
management, identify forward-looking statements. Such statements,
include, but are not limited to, statements contained in this press
release relating to our business strategy, our future operating
results and liquidity and capital resources outlook.
Forward-looking statements are based on our current expectations
and assumptions regarding our business, the economy and other
future conditions. Because forward–looking statements relate to the
future, they are subject to inherent uncertainties, risks and
changes in circumstances that are difficult to predict. Our actual
results may differ materially from those contemplated by the
forward-looking statements. They are neither statements of
historical fact nor guarantees of assurance of future performance.
We caution you therefore against relying on any of these
forward-looking statements. Important factors that could cause
actual results to differ materially from those in the
forward-looking statements include, without limitation, our ability
to raise capital to fund continuing operations; our ability to
protect our intellectual property rights; the impact of any
infringement actions or other litigation brought against us;
competition from other providers and products; our ability to
develop and commercialize products and services; changes in
government regulation; our ability to complete capital raising
transactions; and other factors relating to our industry, our
operations and results of operations. Actual results may differ
significantly from those anticipated, believed, estimated,
expected, intended or planned.
Factors or events that could cause our actual results to differ
may emerge from time to time, and it is not possible for us to
predict all of them. We cannot guarantee future results, levels of
activity, performance or achievements. The Company assumes no
obligation to update any forward-looking statements in order to
reflect any event or circumstance that may arise after the date of
this release.
ContactsImmix Biopharma, Inc.Gabriel
MorrisChief Financial Officerir@immixbio.com+1 (888) 958-1084
Immix Biopharma (NASDAQ:IMMX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Immix Biopharma (NASDAQ:IMMX)
Historical Stock Chart
From Sep 2023 to Sep 2024